T Cell News and Research

Latest T Cell News and Research

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Gloucester Pharmaceuticals announced today the presentation of preclinical data demonstrating that the combination of ISTODAX® (romidepsin) and Velcade® (bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin's lymphoma cell lines.

7 Dec 2009

Scientists explore new strategies for treating neurodegenerative diseases

Studies with fruit flies have shown that the specialized nerve cells called neurons can rebuild themselves after injury.

7 Dec 2009

Smoking cessation offers measurable benefits for asthmatic patients

Asthmatic smokers may be able to reverse some of the damage to their lungs that exacerbates asthmatic symptoms just by putting down their cigarettes, according to research out of the University of Groningen in the Netherlands.

7 Dec 2009

VAI expands to support annual research operation

On December 8, Van Andel Institute (VAI) cuts the ribbon on its eight-story, $178 million, 240,000 square foot Phase II expansion. The expanded facility creates economic and scientific opportunity both for VAI and West Michigan's burgeoning life sciences sector and adds to the more than $1 billion investment in infrastructure already in place along Grand Rapids' Medical Mile.

7 Dec 2009

Albert Einstein College of Medicine receives SU2C grant for cancer research

Matthew Levy, Ph.D., assistant professor of biochemistry at Albert Einstein College of Medicine of Yeshiva University, has been awarded more than $700,000 by Stand Up To Cancer (SU2C) for his high-risk/high-reward cancer research.

7 Dec 2009

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

Cytokinetics, Incorporated announced today that a poster summarizing clinical trial data regarding SB-743921 was presented at the 2009 American Society of Hematology (ASH) Annual Meeting and Exposition held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

7 Dec 2009

Researchers explore optimal induction therapies for managing blood cancer

There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in order to discover new treatment options and provide patients with the best care.

7 Dec 2009

TGFb growth factor controls spread of cancer cells

The spread, or metastasis, of individual breast cancer cells from the main tumor into the blood circulation to the lungs and other body tissues and organs is under the control of a growth factor abbreviated TGFb, according to a study with laboratory mice that will be presented at the American Society for Cell Biology (ASCB) 49th Annual Meeting, Dec. 5-9, 2009 in San Diego.

7 Dec 2009

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

Allos Therapeutics, Inc. today reported new analyses of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

7 Dec 2009

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Alexion Pharmaceuticals, Inc. today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria (PNH) cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells experience ongoing platelet consumption and increased thrombosis risk.

7 Dec 2009

New approach to protein misfolding may lead to novel therapies for a number of diseases

In an encouraging new development, a team led by Scripps Research Institute scientists has restored partial function to lung cells collected from patients with cystic fibrosis. While there is still much work to be done before the therapy can be tested in humans, the discovery opens the door to a new class of therapies for this and a host of other chronic diseases.

7 Dec 2009

Vitamin D supplements may aid in treating cancer

The findings support the growing association between vitamin D and cancer risk and outcomes, and suggest that vitamin D supplements might help even those patients already diagnosed with some forms of cancer, says Dr. Drake.

7 Dec 2009

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients.

7 Dec 2009

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

A new study by researchers from the Medical College of Wisconsin, in Milwaukee, found a substantial variation in hydroxyurea utilization for pain and other sickle cell disease complications in children.

7 Dec 2009

New findings may yield more effective therapies for infants with blood cancer

Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse with another gene to drive an often-fatal form of leukemia in infants. By more accurately defining specific partner genes, researchers expect to better predict which infants may benefit from particular treatments.

7 Dec 2009

ImmunoGen reports encouraging clinical data of IMGN901

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, today reported encouraging clinical data with its IMGN901 product candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed on multiple prior treatment regimens.

6 Dec 2009

Study explains how circadian rhythms can drive feeding and metabolism behaviors

One of the pioneers in research on sleep:wake circadian genes, Amita Sehgal, Ph.D., has discovered that fruit flies' appetite and consumption are controlled by two rival sets of clocks, one in neurons and the other in the fly fat body, which is analogous to the liver.

6 Dec 2009

Positive final data from Phase 2 study of ISTODAX presented

Gloucester Pharmaceuticals announced today the presentation of positive final data from a Phase 2 study of ISTODAX® (romidepsin) in peripheral T-cell lymphoma (PTCL) conducted by the National Cancer Institute (NCI) at the 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, LA.

6 Dec 2009

Stem cell treatment: A new hope for Multiple Sclerosis

RNL Bio Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that a 46-year-old female, Kang Sook Park's Multiple Sclerosis improved tremendously after receiving stem cell treatment. Park was suffering from MS (Multiple Sclerosis), an autoimmune disease that affects the central nervous system (brain and spinal cord).

6 Dec 2009

Bortezomib can improve control of GVHD and immune system recovery

A drug that has become a mainstay of multiple myeloma treatment may outperform alternative therapies in re-establishing the immune system of patients who have received stem cell transplants from unrelated, partially matched donors, according to early clinical trial results to be presented by Dana-Farber Cancer Institute investigators at the American Society of Hematology's (ASH) annual meeting on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial Convention Center, Room 243-245, 5:45 pm CT).

6 Dec 2009

T Cell News and Research

Latest T Cell News and Research

Presentation of preclinical data demonstrating the combination of ISTODAX and Velcade announced

Scientists explore new strategies for treating neurodegenerative diseases

Smoking cessation offers measurable benefits for asthmatic patients

VAI expands to support annual research operation

Albert Einstein College of Medicine receives SU2C grant for cancer research

Poster summarizing clinical trial data regarding SB-743921 presented by Cytokinetics

Researchers explore optimal induction therapies for managing blood cancer

TGFb growth factor controls spread of cancer cells

New analyses of data from Allos Therapeutics’ pivotal PROPEL trial of FOLOTYN reported

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

New approach to protein misfolding may lead to novel therapies for a number of diseases

Vitamin D supplements may aid in treating cancer

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Study finds substantial variation in hydroxyurea utilization for sickle cell disease

New findings may yield more effective therapies for infants with blood cancer

ImmunoGen reports encouraging clinical data of IMGN901

Study explains how circadian rhythms can drive feeding and metabolism behaviors

Positive final data from Phase 2 study of ISTODAX presented

Stem cell treatment: A new hope for Multiple Sclerosis

Bortezomib can improve control of GVHD and immune system recovery

Immunology eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Newsletters you may be interested in